Dabrafenib in metastatic melanoma: a monocentric ‘real life’ experience
Dabrafenib in metastatic melanoma: a monocentric ‘real life’ experience
About this item
Full title
Author / Creator
Cocorocchio, E , Gandini, S , Alfieri, S , Battaglia, A , Pennacchioli, E , Tosti, G , Spadola, G , Barberis, M , Di Leo, M , Riviello, C , Pala, L , Intelisano, A , Martinoli, C and Ferrucci, PF
Publisher
England: Cancer Intelligence
Journal title
Language
English
Formats
Publication information
Publisher
England: Cancer Intelligence
Subjects
More information
Scope and Contents
Contents
Dabrafenib is a potent BRAF-kinase inhibitor. Its activity was evaluated on 40 consecutive metastatic melanoma patients (pts) harboring the V600BRAF mutations. Dabrafenib was administered orally at the dosage of 150 mg b.i.d. daily. ORR was 82%, with 7% CR, 62% PR, 13% SD and 18% PD. The median PFS and OS were seven and 17 months, respectively (med...
Alternative Titles
Full title
Dabrafenib in metastatic melanoma: a monocentric ‘real life’ experience
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4778691
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4778691
Other Identifiers
ISSN
1754-6605
E-ISSN
1754-6605
DOI
10.3332/ecancer.2016.624
